Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 29HER2-positive Breast Cancer 5Neoplasms 3Multiple Myeloma 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Salivary Gland Neoplasms 1Resectable HER2-positive Breast Cancer 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1

Interventions

Pemetrexed 4Spinal Puncture 3Radiotherapy 3aflutinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Bevacizumab 2toripalimab 1sintilimab 1pertuzumab 1lorlatinib 1azeliragon 1adavosertib 1Trastuzumab 1Referral and Consultation 1Radiation 1Physical Examination 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1GDC-0084 1Drug Therapy 1Deferoxamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × pertuzumab × 90 days × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡